COVANCE CLINICAL ONCOLOGY SYMPOSIUM

The Coming of Age of Cellular Immunotherapy for Cancer

Friday, 21 September 2018
10:30 a.m. – Noon

Xiamen International Conference & Exhibition Center
Building C5, Room 215
Xiamen, China

We are pleased to invite you to the Covance Clinical Oncology Symposium in Xiamen. Join our experts as they discuss cell-based immunotherapy and companion diagnostic strategies for cancer.

A networking lunch will follow the presentations.

Please RSVP to: Shirley Zheng - Shirley.Zheng@covance.com

TOPICS AND SPEAKERS

Welcome
Honggang Bi, PhD
Corporate Vice President, General Manager, China

Dr. Bi has more than 18 years of management experience in pharmaceutical research and development, such as Frontage Laboratories, Pfizer, Parke-Davis and SmithKline Beecham Pharmaceuticals. His responsibilities include managing Covance China revenue and profit growth as well as expanding the company’s service offerings.

Regulatory Considerations for Genetically Modified Cell-Based Cancer Immunotherapy Products
Beatriz Rocha, MD, PhD,
Vice President, Head Global Regulatory Affairs

Dr. Rocha is a worldwide recognized expert in the area of addiction and abuse liability. She serves in the College on Problems of Drug Dependence (CPDD) Board of Directors, and is the chief operating officer of the Cross Company Abuse Liability Council (CCALC). At Covance, Dr. Rocha currently heads Global Regulatory Affairs (GRA) and the Strategic Product Development Consulting group that offers overall regulatory and medical consultancy across the entire continuum of drug and medical devices development.
Cell-Therapy for Cancer: Clinical Progress, Pitfalls and Future Prospects

Jelle Kijlstra, MD, MBA  
*Senior Director, Hematology/Oncology*

As senior director at Chiltern, a Covance company, Dr. Kijlstra leads the North American Oncology Therapy Area, and acts as the medical monitor for oncology studies primarily involving hematologic malignancies. In his 28 years of industry experience, including working for Zeneca, Dendreon, Spectrum, and several other U.S. biotech firms, he successfully led nine oncology and cellular immunology drugs, as well as two interventional oncology surgical devices to FDA and EMA approval. He has broad experience in oncology clinical trials (Phases I-III) in solid tumors, hematologic malignancy, immuno-oncology and tumor targeted surgical devices. He is also the patent holding co-inventor of Provenge™, an immunotherapy drug for prostate cancer (FDA approved, 2010). Dr. Kijlstra has presented for FDA advisory boards, and has published several dozen peer-reviewed papers and abstracts.

Companion Diagnostic Strategies to Support Immuno-Oncology Development

Thomas Turi, PhD  
*Vice President, Companion Diagnostics*

Thomas Turi, PhD is vice president Companion Diagnostics for Covance Central Laboratory Services. He joined Covance in 2008 to establish the Biomarker Center of Excellence and was integral to the acquisition of the Covance Genomics Laboratory and the formation of Discovery and Translational Services. He is currently responsible for Covance’s Companion Diagnostics efforts and leads operations for the newly launched companion diagnostics development laboratory. Prior to Covance, Dr. Turi spent 15 years in the pharmaceutical industry, where he held a broad array of scientific leadership positions of increasing responsibility. Most recently he served as the senior director of Translational Biomarkers and Mechanistic Biology at Pfizer.

In addition to his current responsibilities, Dr. Turi has served on the Board of Trustees for The Life Sciences Foundation and is a member of the Global Health Research Roundtable of the Indiana Clinical and Translational Sciences Institute. He has previously served on the Board of Directors for Caprion Proteomics and led several external partnerships including those with Rules Based Medicine, Celera, Incyte, and Affymetrix. He has also served on grant and program project review boards for NASA’s Section for Biotechnology and Tissue Engineering.

Dr. Turi received dual bachelor degrees in Biochemistry and Chemistry from the University of Illinois at Urbana-Champaign and his doctorate in Molecular Genetics from the University of Cincinnati College of Medicine. He completed postdoctoral training at the Yale University School of Medicine applying molecular genetic techniques to investigate the mechanisms of protein transport.
We look forward to your attendance.

Please RSVP to: Shirley Zheng - Shirley.Zheng@covance.com

Learn more about our drug development solutions at www.covance.com